The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison
| Autor: | J. Franz-Werner, R Weide, A. D. Ho, Michael Rieger, Peter Dreger, Julia Meissner, Mathias Witzens-Harig, W. Knauf, Thomas Luft, Manfred Hensel, Peter Stadtherr, Thorsten Zenz, M. Procaccianti, Stefan Schönland, M. Görner, Axel Benner, Manfred Welslau, T H Tran, Sascha Dietrich, Isabelle Herth, Ute Hegenbart, Andrea Bondong |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Risk Oncology medicine.medical_specialty Multivariate analysis Chronic lymphocytic leukemia Kaplan-Meier Estimate Disease-Free Survival Internal medicine medicine Clinical endpoint Humans Transplantation Homologous Aged Proportional Hazards Models Retrospective Studies Proportional hazards model business.industry Hazard ratio Retrospective cohort study Hematology Middle Aged medicine.disease Leukemia Lymphocytic Chronic B-Cell Tissue Donors Confidence interval Transplantation Treatment Outcome Multivariate Analysis Female business Stem Cell Transplantation |
| Zdroj: | Annals of Oncology. 25:200-206 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdt511 |
| Popis: | Background In a single-center retrospective donor versus no-donor comparison, we investigated if allogeneic stem cell transplantation (alloSCT) can improve the dismal course of poor-risk chronic lymphocytic leukemia (CLL). Patients and methods All patients with CLL who were referred for evaluation of alloSCT within a 7-year time frame and had a donor search indication according to the EBMT criteria or because of Richter's transformation were included. Patients for whom a matched donor could be found within 3 months (matches) were compared with patients without such a donor (controls). Primary end point was overall survival measured from the 3-month landmark after search initiation. Results Of 105 patients with donor search, 97 (matches 83; controls 14) were assessable at the 3-month landmark. Matches and controls were comparable for age, gender, time from diagnosis, number of previous regimens, and remission status. Disregarding if alloSCT was actually carried out or not, survival from the 3-month landmark was significantly better in matches versus controls [hazard ratio 0.38, 95% confidence interval (CI) 0.17–0.85; P = 0.014]. The survival benefit of matches remained significant on multivariate analysis. Conclusion This study provides first comparative evidence that alloSCT may have the potential to improve the natural course of poor-risk CLL as defined by the EBMT criteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|